3110037I16Rik Inhibitors
Chemical inhibitors of the protein 3110037I16Rik can modulate its activity by targeting various signaling pathways and kinases that are potentially involved in its regulation. Staurosporine is known for its broad-spectrum inhibition of protein kinases, and as such, it can inhibit the activity of 3110037I16Rik if its function is mediated through kinase activity or through regulation by phosphorylation. Similarly, LY294002 and Wortmannin act as inhibitors of PI3K, leading to a decrease in AKT activation. If 3110037I16Rik is regulated by or dependent on the PI3K/AKT signaling pathway, these inhibitors can effectively reduce its activity. Additionally, PD98059 and U0126 target the MEK1 and MEK2 enzymes, respectively, and by doing so, they can reduce the activation of the ERK pathway. If 3110037I16Rik operates downstream of the MAPK/ERK pathway, the use of these inhibitors can result in its decreased activity.
Further influencing the activity of 3110037I16Rik, SB203580 and SP600125 specifically target p38 MAPK and JNK pathways. If 3110037I16Rik is a downstream component or is regulated by these pathways, its activity can be inhibited by these selective inhibitors. Rapamycin, an inhibitor of mTOR, can also decrease the activity of 3110037I16Rik if it is involved in processes such as protein synthesis and cell proliferation that are controlled by mTOR signaling. PP2, which inhibits Src family tyrosine kinases, can diminish the activity of 3110037I16Rik if Src kinase signaling plays a role in its regulation. Y-27632 targets the Rho signaling pathway by selectively inhibiting ROCK, which can lead to the inhibition of 3110037I16Rik if it is regulated by Rho/ROCK pathway dynamics. PD173074 and ZM-447439, which are selective inhibitors of FGFR tyrosine kinase and Aurora kinases respectively, can also inhibit the activity of 3110037I16Rik if it is involved in signaling pathways or cell cycle regulation mediated by these kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. If 3110037I16Rik functions as a kinase or is regulated by phosphorylation, staurosporine can inhibit its activity by preventing its phosphorylation or the phosphorylation of proteins that regulate 3110037I16Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, a kinase involved in many signaling pathways. Inhibition of PI3K can lead to decreased AKT activation, which may inhibit 3110037I16Rik activity if 3110037I16Rik is AKT-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK in the MAPK pathway. Inhibition of MEK therefore leads to reduced ERK activity which can inhibit 3110037I16Rik if the protein operates downstream of the MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also specifically inhibits MEK, and through this action, it can inhibit the MAPK pathway. If 3110037I16Rik's function is modulated by the MAPK pathway, then U0126 will inhibit the protein's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3K. By inhibiting PI3K, it can diminish AKT phosphorylation and activity, leading to inhibition of downstream proteins such as 3110037I16Rik if it is regulated by PI3K/AKT signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can lead to decreased activation of downstream targets, potentially including 3110037I16Rik if it is a part of the p38 MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which can inhibit the JNK signaling pathway. If 3110037I16Rik is a component or a regulatory target of the JNK pathway, the protein's activity will be inhibited. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is involved in cell growth and proliferation. Inhibition of mTOR can lead to decreased protein synthesis and cell proliferation, inhibiting 3110037I16Rik if it is involved in these processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. If 3110037I16Rik's activity is regulated by Src kinase signaling, PP2 can inhibit the protein by inhibiting Src family kinases. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 selectively inhibits ROCK, which is part of the Rho signaling pathway. By inhibiting ROCK, Y-27632 can inhibit 3110037I16Rik if the protein is regulated by the Rho/ROCK pathway. | ||||||